From the Bench to Bedside: Closing the Signaling Gap in Wound Healing and Skin Regeneration

Fundamental to understanding the biology of wound healing and skin regeneration is the knowledge of the signals that trigger skin cells to migrate, proliferate, differentiate, and lay down new matrix. Arava Bio-Tech is developing a topical drug- AR101- a formulation combined of two API’s where each API promotes selective parameters in skin physiology. When combined, AR101 augments synergistically skin regeneration and healing parameters and can overcome the pathological processes associated with hard to heal wounds. Arava Bio-Tech has established that the insulin signalling pathway is involved directly in skin regeneration and healing, processes which are mediated by the Protein Kinase C (PKC) family of serine-threonine kinases. In various animal models and consequently in phase II clinical trials, the effects of of AR101 on various parameters including re-epithelialization, formation of granulation tissue and attenuation of the severe inflammatory response was studied. Quantitative results of animal testing and human studies demonstrate that the PKC‑modulating drug can induce epithelialization, skin regeneration and wound healing.